Structure Therapeutics Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; balance-sheet comparisons are with December 31, 2023. Amounts below are in U.S. dollars. The company is a clinical-stage biopharmaceutical business focused on oral small-molecule therapeutics and has no approved products or product revenue.
Financial performance and liquidity
| Metric | Q1 2024 | Q1 2023 / comparison |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $20.7 million | $13.1 million; up 57% |
| General and administrative expense | $11.3 million | $6.5 million; up 74% |
| Total operating expenses / operating loss | $32.0 million | $19.6 million |
| Interest and other income, net | $6.0 million | $1.7 million |
| Net loss | $26.0 million | $18.0 million |
| Net loss per share, basic and diluted | $0.19 | $0.25 |
| Cash used in operating activities | $34.1 million | $20.3 million |
| Cash, cash equivalents and short-term investments | $436.4 million at March 31 | $467.3 million at December 31 |
Cash and cash equivalents were $97.8 million and short-term investments were $338.6 million at quarter-end. Total assets were $457.2 million; total liabilities were $27.4 million, including $5.1 million of operating lease liabilities. The filing reports no material funded debt. Accumulated deficit was $232.6 million. Margins are not meaningful because the company had no revenue.
Management attributes higher operating expenses to advancement of the GLP-1R franchise and other research programs, clinical activity, increased personnel and public-company costs. Higher interest income reflected higher rates and investment balances. The larger year-over-year loss per share is masked by the increase in weighted-average shares following the 2023 IPO and subsequent financing.
Management’s runway statements differ in specificity: the financial-statement note says existing resources are sufficient for at least 12 months from issuance, while MD&A and the risk discussion estimate funding through at least 2026, based on the current plan and assumptions. Management cautions that resources could be exhausted sooner than expected.
Business developments, outlook and risks
- GSBR-1290: Oral GLP-1R candidate for obesity and type 2 diabetes. Management expects full 12-week Phase 2a obesity data and high-level capsule-to-tablet formulation bridging results in June 2024. It expects to start a global Phase 2b obesity study in Q4 2024 and a Phase 2 type 2 diabetes study in the second half of 2024. These are forward-looking expectations, not guarantees.
- Previously reported Phase 2a results included significant HbA1c and weight reductions in the type 2 diabetes cohort and weight reduction at eight weeks in the obesity cohort. Results were preliminary; no treatment-related serious adverse events were reported in the 12-week study. A clinical-site omission meant week-12 weight was not collected for 24 of 40 participants in the obesity cohort at the 120 mg dose; replacement participants were enrolled, delaying complete results.
- Pipeline: GSBR-1290 and ANPA-0073 are in early clinical development; other programs, including LTSE-2578, are earlier-stage. ANPA-0073 is being developed for idiopathic pulmonary fibrosis. The company expects substantial and increasing R&D expense and operating losses and will require additional capital over time.
- Manufacturing and collaboration exposure: The company relies on third parties and identifies WuXi STA as its current single-source supplier for active pharmaceutical ingredient and drug product, while pursuing alternative suppliers, including outside China. Schrödinger is a related-party collaborator; Q1 payments were $1.0 million. Agreements include potential milestone payments of up to $17 million and $89 million, respectively, plus low-single-digit royalties if qualifying products are developed and commercialized; no such milestones or royalties were paid or accrued at quarter-end.
- Controls: Management concluded disclosure controls were not effective at March 31, 2024. A material weakness remains because the company lacked enough financial-reporting professionals to maintain an effective control environment. Management has hired additional accounting and controls personnel; remediation is not complete. The weakness had not resulted in a material misstatement in the reported statements.
- Other risks and contingencies: Clinical and regulatory uncertainty, adverse events, trial enrollment or data-quality problems, competition, intellectual-property protection, access to capital, and geopolitical, macroeconomic and U.S.–China developments could affect the business. The company reported no known legal matters expected to have a material adverse effect and no material indemnification claims accrued. It reported no significant financial impact from recent geopolitical or macroeconomic developments in the quarter.
Important facts for investors to verify
- Whether the complete Phase 2a obesity results and formulation-bridging data were reported as expected, and how they compare with preliminary findings.
- Whether the Phase 2b obesity and Phase 2 type 2 diabetes studies begin on the stated timelines, and their design, enrollment and cost implications.
- The basis and assumptions behind the stated cash runway through at least 2026, particularly given the note’s less-specific 12-month statement and Q1 operating cash use of $34.1 million.
- Progress in qualifying alternative manufacturing suppliers and the potential effect of reliance on a China-based single source and U.S.–China policy changes.
- Whether management remediates the material weakness and establishes effective disclosure and financial-reporting controls.
- Potential dilution from future financing and equity compensation; ordinary shares outstanding were 139.9 million at April 30, 2024.